EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

APOE4-promoted gliosis and degeneration in tauopathy are ameliorated by pharmacological inhibition of HMGB1 release

Nicole Koutsodendris, Jessica Blumenfeld, Ayushi Agrawal, Michela Traglia, Oscar Yip, Antara Rao, Min Joo Kim, Maxine R Nelson, Yung-Hua Wang, Brian Grone, Yanxia Hao, Reuben Thomas und 4 weitere

Cell Reports · 2023-10 · 42 (10) · 113252

DOI: 10.1016/j.celrep.2023.113252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2023-10. Verfasst von Nicole Koutsodendris und 15 weiteren Autor:innen. Beteiligte Einrichtung: Gladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA 94158, USA; Developmental and Stem Cell Biology Graduate Program…. Hauptthemen laut MEDLINE: Alzheimer Disease, HMGB1 Protein, Tauopathies. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NICHD NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Apolipoprotein E4 (APOE4) is an important driver of Tau pathology, gliosis, and degeneration in Alzheimer's disease (AD). Still, the mechanisms underlying these APOE4-driven pathological effects remain elusive. Here, we report in a tauopathy mouse model that APOE4 promoted the nucleocytoplasmic translocation and release of high-mobility group box 1 (HMGB1) from hippocampal neurons, which correlated with the severity of hippocampal microgliosis and degeneration. Injection of HMGB1 into the hippocampus of young APOE4-tauopathy mice induced considerable and persistent gliosis. Selective removal of neuronal APOE4 reduced HMGB1 translocation and release. Treatment of APOE4-tauopathy mice with HMGB1 inhibitors effectively blocked the intraneuronal translocation and release of HMGB1 and ameliorated the development of APOE4-driven gliosis, Tau pathology, neurodegeneration, and myelin deficits. Single-nucleus RNA sequencing revealed that treatment with HMGB1 inhibitors diminished disease-associated and enriched disease-protective subpopulations of neurons, microglia, and astrocytes in APOE4-tauopathy mice. Thus, HMGB1 inhibitors represent a promising approach for treating APOE4-related AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHMGB1 ProteinTauopathiesAnimalsMiceApolipoprotein E4GliosisMice, TransgenicApolipoproteins E

Stichwörter der Autor:innen

APOE4Alzheimer's diseaseCP: NeuroscienceDAADAMHMGB1astrocytosismicrogliosismyelin deficitneurodegenerationtau pathology

Substanzen

Apolipoprotein E4HMGB1 ProteinApoe protein, mouseApolipoproteins EHMGB1 protein, mouse

Autor:innen und Institutionen

  • Gladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA 94158, USA; Developmental and Stem Cell Biology Graduate Program, University of California, San Francisco, San Francisco, CA 94143, US…
  • Gladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA 94158, USA; Neuroscience Graduate Program, University of California, San Francisco, San Francisco, CA 94158, USA.
  • Gladstone Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA 94158, USA.
  • Gladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA 94158, USA; Biomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Gladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA 94158, USA; Gladstone Center for Translational Advancement, Gladstone Institutes, San Francisco, CA 94158, USA.
  • Gladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA 94158, USA.

Förderung

  • NIA NIH HHS
  • NICHD NIH HHS
  • National Institutes of Health

Zitieren

APA

Koutsodendris, N., Blumenfeld, J., Agrawal, A., Traglia, M., Yip, O., Rao, A., Kim, M. J., Nelson, M. R., Wang, Y. H., Grone, B., Hao, Y., Thomas, R., Zilberter, M., Yoon, S. Y., Arriola, P., & Huang, Y. (2023). APOE4-promoted gliosis and degeneration in tauopathy are ameliorated by pharmacological inhibition of HMGB1 release. Cell Reports, 42(10), 113252. https://doi.org/10.1016/j.celrep.2023.113252

Vancouver

Koutsodendris N, Blumenfeld J, Agrawal A, Traglia M, Yip O, Rao A, et al. APOE4-promoted gliosis and degeneration in tauopathy are ameliorated by pharmacological inhibition of HMGB1 release. Cell Reports. 2023;42(10):113252. doi:10.1016/j.celrep.2023.113252

BibTeX
@article{Koutsodendris2023,
  author = {Koutsodendris, Nicole and Blumenfeld, Jessica and Agrawal, Ayushi and Traglia, Michela and Yip, Oscar and Rao, Antara and Kim, Min Joo and Nelson, Maxine R and Wang, Yung-Hua and Grone, Brian and Hao, Yanxia and Thomas, Reuben and Zilberter, Misha and Yoon, Seo Yeon and Arriola, Patrick and Huang, Yadong},
  title = {APOE4-promoted gliosis and degeneration in tauopathy are ameliorated by pharmacological inhibition of HMGB1 release},
  journal = {Cell Reports},
  year = {2023},
  volume = {42},
  number = {10},
  pages = {113252},
  doi = {10.1016/j.celrep.2023.113252}
}
Kostenlos starten →